In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Concert Pharmaceuticals Inc.

Latest From Concert Pharmaceuticals Inc.

Phase III Study Failure Clouds Future Of Avanir’s Alzheimer’s Agitation Candidate

Otsuka’s Avanir hit by failed second trial in Phase III program with candidate for agitation associated with Alzheimer’s, prompting a re-think of development plans and potentially helping rivals in a high-need indication.


Clinical Trials Neurology

Concert Looks To Phase III In Alopecia Areata, Ahead Of Pfizer’s JAK Inhibitor

Concert believes its deuterated form of ruxolitinib has a better overall profile in alopecia areata than Pfizer’s JAK3 inhibitor. The company is planning to meet with the FDA to plan a Phase III program early in 2020.

Clinical Trials Business Strategies

Otsuka’s Avanir Encouraged By First Peek At Treatment For Alzheimer’s Agitation

Phase III results from Avanir’s candidate for agitation in patients with Alzheimer’s disease offers some hope in a setting for which there is no specific treatment.

Clinical Trials Neurology

Concert Says Phase II Alopecia Drug Could Beat Pfizer’s Candidate To Market

While Pfizer’s JAK3 inhibitor is in Phase II/III for alopecia areata, Concert thinks its deuterium-modified ruxolitinib may get to market sooner. However, the breadth of Incyte’s ruxolinitib patent protection is unclear.

Commercial Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Concert Pharmaceuticals Inc.
  • Senior Management
  • Roger Tung, PhD, Pres. & CEO
    Marc Becker, CFO
    James V Cassella, PhD, Chief Dev. Officer
    Nancy Stuart, COO
  • Contact Info
  • Concert Pharmaceuticals Inc.
    Phone: (781) 860-0045
    65 Hayden Ave.
    Ste. 3000N
    Lexington, MA 02421